Bank of America has thrown its weight behind Galderma ahead of the Swiss skincare and aesthetics company's third-quarter earnings report, scheduled for Oct. 22. In a note to clients, BofA Global Research said it expects Galderma to deliver another "beat-and-raise" — a quarter where results exceed analyst estimates and management lifts its forward guidance.
Specifically, the bank is modeling 22.2% sales growth on a constant-currency basis, which strips out the effects of currency fluctuations to give a cleaner picture of underlying performance. That figure sits roughly 2.7 percentage points above the consensus estimate among analysts covering the stock.
Why BofA is optimistic
BofA's confidence rests on expected strength across all three of Galderma's business divisions. The first, Injectable Aesthetics, includes products like Relfydess, a neuromodulator that the company is rolling out internationally. Neuromodulators are substances that temporarily relax facial muscles — the same category as Botox — and they represent a high-margin, fast-growing segment of the medical aesthetics market.
The second division, Derma skincare, is anchored by Cetaphil, a brand familiar to many consumers. BofA points to momentum for Cetaphil in China and India, two large and expanding markets where rising middle classes are spending more on personal care. The third division, Therapeutic Dermatology, focuses on prescription treatments for skin conditions. Here, BofA believes generic competition is having less of an impact than some investors had feared.
The bank also highlights a favorable shift in Galderma's product mix — meaning a larger share of sales is coming from higher-growth, higher-margin products. If management confirms that trend on Oct. 22, it could reinforce the case that Galderma is not just growing, but growing profitably.
What 'beat and raise' means for investors
In quarterly earnings, a "beat" means the company reported revenue or profit above what analysts expected. A "raise" means management increased its own forecast for future periods. Together, a beat-and-raise is often seen as a sign of business momentum, because it suggests not only that the past quarter was strong but that the company sees continued strength ahead.
For everyday investors, the key takeaway is that BofA's estimate is meaningfully above the consensus. If Galderma does report 22.2% constant-currency growth, it would likely surprise many analysts and could prompt upward revisions to full-year forecasts. However, it's important to remember that analyst estimates are just projections — they can be wrong, and the actual results may differ.
Galderma is a relatively recent addition to the public markets, having listed on the Swiss stock exchange in 2024. As a newer entrant, it may not yet have the long track record that larger, more established consumer-health companies have. That can make quarterly results more volatile and harder to predict.
The broader context
Galderma operates at the intersection of healthcare and consumer discretionary spending. Its aesthetics products are often elective, meaning demand can be sensitive to economic conditions — when consumers feel less confident, they may postpone non-essential treatments. Its skincare brands, meanwhile, compete in a crowded global market against giants like L'Oréal and Unilever.
Still, the aesthetics and dermatology markets have grown steadily in recent years, driven by aging populations, rising disposable incomes in emerging markets, and increasing social acceptance of cosmetic procedures. Companies that can capture share in these niches often command premium valuations.
Currency movements are another factor. Galderma reports in Swiss francs but generates sales globally, so swings in exchange rates can distort headline growth. That's why BofA and other analysts focus on constant-currency figures, which provide a more apples-to-apples comparison across periods.
What to watch on Oct. 22
When Galderma reports, investors will be looking for several things. First, whether actual sales growth meets, beats, or misses BofA's 22.2% estimate. Second, any commentary on Relfydess's international rollout — how quickly it's gaining traction and in which markets. Third, updates on Cetaphil's performance in China and India, which are key growth engines. Fourth, management's guidance for the remainder of the year and into 2026.
Beyond the numbers, investors will listen for any signs of pricing pressure, competitive dynamics, or changes in consumer behavior. In the aesthetics space, for example, new entrants or discounting by rivals could weigh on margins.
For those holding or considering Galderma shares, the report will be a test of whether the company can sustain its early momentum as a public company. A strong quarter and raised guidance could bolster confidence; a miss could raise questions about the durability of its growth story.
As always, no single earnings report should drive an investment decision on its own. Investors should consider Galderma's valuation, competitive position, and long-term prospects alongside any short-term quarterly results.
